Trial
NCT04227275
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Tceleron Therapeutics, Inc.
Collaborators
—
Condition
Metastatic Castration-resistant Prostate Cancer
Intervention
CART-PSMA-TGFβRDN
Why stopped
Based on the safety events and evidence of biologic activity without sustained clinical responses the Sponsor finds the risk/benefit analysis unfavorable for patients and has terminated the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-21